Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong David Buswell?

David Buswell

Chief Executive Officer

Immune Response BioPharma Inc

Direct Phone: (609) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Chief Executive Officer and Chief Financial Officer and Chief Operating Officer

The Immune Response Corporation


Not Applicable

The Corporate Agent


Web References(14 Total References)


Executive Team

www.immuneresponsebiopharma.com [cached]

Chief Operating Officer & Chief Financial Officer & CEO: Mr. David Buswell
Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO, President & acting CEO and is Chairman of the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Management & Leadership from Liberty University.


immuneresponsebiopharma.com

Chief Operating Officer & Chief Financial Officer Mr. David Buswell
Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO and is on the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Leadership & Management from Liberty University.


www.valuebasedrheumatology.com

Orphan designation will allow for a more speedy development of RAVAX and will give us further flexibility in trial design and expand the RA vaccine use into the rare disease, JRA [juvenile RA], said David Buswell, Chief Operating Officer and Interim Chief Executive Officer of Immune Response BioPharma.


In the Pipeline:

pipeline.corante.com [cached]

Update: Immune Response Biopharma CEO David Buswell has left a detailed comment to this point, pointing out that it was his company that ended talks with GSK, and not the other way around.
See here for the details. GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell "IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell Y'know, in his way, this CEO is a breath of fresh air. Everyone thinks these things in such situations, but not many people put them out on the PR wires. This release seems to have transcribed directly from Mr. Buswell's (no doubt heated) statements at the time, which I'm sure accounts for the take-a-breath grammar.


www.napc.co.uk

David Buswell, the chief executive of Immune Response Biopharma, has let rip at GlaxoSmithKline in the wake of an apparently acrimonious breakdown in talks over a tie-up involving a multiple sclerosis drug.
Mr Buswell accused GSK's Sir Andrew Witty of 'wasting money' on a £2.6 billion takeover bid for Human Genome Sciences and of devoting resources to the newly approve Benlysta, 'a lupus drug with poor sales'.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory